Chapter 9. Human Immunodeficiency Virus
1. Greene KB, Berger J, Reeves C et al. Most frequently used alternative and complementary therapies and activities by participants in the AMCOA study. J Assoc Nurses AIDS Care, 1999; 10:60-73.
2. Hsiao AF, Wong MD, Kanouse DE et al. Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. J Acquir Immune Defic Syndr, 2003; 33:157-165.
3. Bica I, Tang AM, Skinner S et al. Use of complementary and alternative therapies by patients with human immunodeficiency virus disease in the era of highly active antiretroviral therapy. J Altern Complment Med, 2003; 9: 65-76.
4. Dhalla S, Chan KJ, Montaner JSG, Hogg RS. Complementary and alternative medicine use in British Columbia—a survey of HIV positive people on anti- retroviral therapy. Complement Ther Clin Pract, 2006; 12: 242-248.
5. Anderson W, O’Connor B, MacGregor R et al. Patient use and assessment of conventional and alternative therapies for HIV infection and AIDS. AIDS, 1993; 7: 561-566.
6. Langewitz W, Ruttimann S, Laifer G et al. The integration of alternative treatment modalities in HIV infection: the patient’s perspective. J. Psychosom Res,1994; 38:687-693.
7. Foote-Ardah, CE. Sociocultural barriers to the use of complementary and alternative medicine for HIV. Qualitative Health Research, 2004; 14:593-611.
8. Piscitelli SC, Burstein AH, Chaitt D et al. Indinavir concentrations and St. John’s wort. Lancet, 2000; 355:547-548.
9. De Maat MMR, Hoetelmans RMW, van Gorp ECM et al. A potential inter- action between St. John’s wort and nevirapine? First International Workshop on Clinical Pharmacology of HIV Therapy, Abstract 2.8, 2000; Netherlands.
10. Piscitelli SC, Burstein AH, Welden N et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis, 2002; 34:234-238.
11. Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy, 2002; 22:551-556.
12. Jernewall N, Zea MC, Reisen CA, Popper PJ. Complementary and alternative medicine and adherence to care among HIV-positive Latino gay and bisexual men. AIDS Care, 2005; 17: 601-609.
13. Risa KJ, Nepon L, Justis JC et al. Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. Int J STD AIDS; 2002; 13: 706-713.
14. Fairfield KM, Eisenberg DM, Davis RB et al. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV- infected patients. Arch Intern Med, 1998; 158:2257-2264.
15. de Visser R, Ezzy D, Bartos M. Alternative or complementary? Allopathic therapies for HIV/AIDS. Altern Ther Health Med, 2000; 6:44-52.
16. Kassler WJ, Blanc P, Greenblatt R. The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med, 1991; 151:2281-2287.
17. Sangkitporn S, Shide L, Klinbuayaem V et al. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV- infected Thai patients. Southeast Asian J Trop Med Public Health, 2005; 36: 704-708.
18. Weber R, Christen L, Loy M et al. Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1 infected individuals. J Acquir Immune Defic Syndr, 1999; 22:56-64.
19. Sherer R, Dutta B, Anderson R, et al. A phase IB study of (+)-calanolide A in HIV-1 infected, antiretroviral therapy naïve patients. 7th Conference on Retrovirus and Opportunistic Infections, 2000, San Francisco.
20. Fawzi W. Micronutrients and human immunodeficiency virus type 1 disease progression among adults and children. Clin Infect Dis, 2003; 37(suppl 2): S112-S116.
21. Jones CY, Tang AM, Forrester JE et al. Micronutrient levels and HIV disease status in HIV-infected patients on highly active antiretroviral therapy in the nutrition for healthy living cohort. J Acquir Immune Defic Syndr, 2006; 43: 475-482.
22. Kaiser JD, Campa AM, Ondercin, JP et al. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial. J Acquir Immune Defic Syndr, 2006; 42: 523-528.
23. Hurwitz BE, Klaus JR, Llabre MM et al. Suppression of human immuno- deficiency virus type 1 viral load with selenium supplementation. Arch Intern Med, 2007; 167: 148-154.
24. Fawzi WW, Msmanga GI, Spiegelman D et al. A randomized trial of multi-vitamin supplements and HIV disease progression and mortality. N Eng J Med, 2004; 351: 23-32.
25. Ackermann RT, Mulrow CD, Ramirez G et al. Garlic shows promise for improving some cardiovascular risk factor. Arch Intern Med, 2001; 161: 813-824.
26. Patrick L, Uzick M. Cardiovascular: c-reactive protein and the inflammatory disease paradigm: HMG-CoA reductive inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev, 2001;6:248-271.
27. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med, 2006;145:474-475
28. Abrams DI, Couey P, Shade SB et al. Antihyperlipidemic effect of Pleurotus ostreatus(Jacq.: Fr.) P. Kumm in HIV: Results of a pilot proof-of-principle clinical trial. International Journal of Medicinal Mushrooms, 2005; 7:339-340.
29. Kris-Etherton PM, Harris WS, Appel LJ and from the American Heart Association Nutrition Committee. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003; 23: 151-152.
30. De Truchis P, Kirstetter M, Perier A et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy. A randomized prospective study. J Acquir Immune Defic Syndr, 2007;44: 278-285.
31. Wohl DA, Tien HC, Busby M et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy—associated hypertrigly-ceridemia. Clin Infect Dis, 2005; 41: 1498-1504.
32. Rambaldi A, Jacobs B, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev, 2007.
33. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of of patients with HIV infection. JAMA, 2001; 286: 2857-2864.
34. Mayne TJ, Vittinghoff E, Chesney MA et al. Depressive affect and survival among gay and bisexual men infected with HIV, 1996; 156: 2233-2238.
35. Linde K, Mulrow CD, Berner M, Egger M. St. John’s wort for depression. Cochrane Database Syst Rev, 2005.
36. Shippy RA, Mendez D, Jones K et al. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry, 2004; 4:38.
37. Rabkin JG, McElhiney MC, Rabkin R et al. Placebo-controlled trial of dehydro-epiandrosterone(DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry, 2006; 163: 59-66/
38. Furler MD, Einarson TR, Millson M et al. Medicinal and recreational marijauna use by patients infected with HIV. AIDS Patient Care STDS, 2004; 18: 215-228.
39. Abrams DI, Hilton JF, Leiser RJ et al. Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial. Ann Intern Med, 2003; 139: 258-266.
40. Abrams DI, Shade SB, Couey P et al. Dehydroepiandrosterone(DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res Hum Retroviruses, 2007; 23: 77-85.
41. Ulmar S, Feleke G, Roginsky MS. Effect of dehydroepiandrosterone (DHEA) n clinical and laboratory parameters in female patients with AIDS(42373). In: Abstracts of the XIIth International Conference on AIDS, 1998 p 848, Geneva.
42. Sekkas GK et al. Creatine supplementation fails to augment the benefit derived from resistance exercise training in patients with HIV infection. Antiviral Ther, 2005; 10:L6.
43. Shabert J, Winslow C, Shabert JK. Glutamine/antioxidant supplementation promotes gain in body cell mass in HIV patients with weight loss(42336). In: Abstracts of the XIIth International Conference on AIDS, 1998, p 841, Geneva.
44. Ferrari S, Vento S, Monaco S. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc, 2006; 81: 213-219.
45. Hart AM, Wilson ADH, Montovani C et al. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS, 2004;18: 1549-1560.
46. Shlay JC, Chaloner K, Max MB et al. Acupuncture and amitriptyline for pain due to HIV-related neuropathy: a randomized controlled trial. JAMA, 1998;280: 1590-1585.
47. Phillips KD, Skelton WD, Hand GA. Effect of acupuncture administered in a group setting on pain and subjective peripheral neuropathy in persons with human immunodeficiency virus disease. J Altern Complment Med, 2004; 10: 449-455.
48. Chang B-H, Boehmer U, Zhao Y, Sommers E. The combined effect of relaxation response and acupuncture on quality of life in patients with HIV: a pilot study. J Altern Complment Med, 2007; 13: 807-815.
49. Ellis MR, Vinson DC, Ewigman B. Addressing spiritual concerns of patients, family physicians’ attitudes, and practices. J Fam Prac, 1999; 48: 105-109.
50. Fitzpatrick AL, Standish LJ, Berger J et al. Survival in HIV-1-positive adults practicing psychological or spiritual activities for one year. Altern Ther Health Med, 2007; 13: 18-20, 22-4.
51. Meredith KL, Jeffe DB, Mundy LM, Fraser VJ. Sources of influencing patients in their HIV medication decisions. Health Education & Behavior, 2001; 28: 40-50.
52. Kaldjian LC, Jekel JF, Friedland G. End-of-life decisions in HIV-positive patients: the role of spiritual beliefs. AIDS, 1998; 12: 103-107.
53. Sicher F, Targ E, Moore D, Smith HS. A randomized double-blind study of the effect of distant healing in a population with advanced AIDS. Report of a small scale study. West J Med, 1998; 169: 356-363.
54. Astin JA, Stone J, Abrams DI et al. The efficacy of distant healing for HIV: results of a randomized trial. Altern Ther Health Med, 2006; 12: 36-41.
55. Birk TJ, MacArthur RD, McGrady A et al. Lack of effect of 12 weeks of massage therapy on immune function and quality of life in HIV-infected person(Th.B.4105). In: Abstracts of the XIth International Conference on AIDS, 1996 p 270, Vancouver.
| The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. |